GlassScriptPhysician profile
Jason Batalha
NPI 1013468149
$1,393.57
in general payments reported to CMS, 2019-2025
15 companies · $665 in 2025
The $665 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $165 · 2023: $166 · 2024: $285 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $508.16 | 2024-2025 | Yescarta |
| Incyte Corporation | $228.28 | 2021-2025 | Niktimvo, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $157.37 | 2022-2025 | Prevymis, Zerbaxa, Dificid |
| Sanofi-Aventis U.S. LLC | $123.04 | 2024-2025 | |
| Amgen INC. | $62.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.76 | 2022-2023 | Iclusig |
| Janssen Biotech, INC. | $43.85 | 2022-2025 | Carvykti |
| Genzyme Corporation | $43.25 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $29.29 | 2021 | |
| Jazz Pharmaceuticals INC. | $28.63 | 2023 | |
| Seagen INC. | $26.33 | 2023 | Adcetris |
| Genentech USA, INC. | $25.69 | 2023 | Venclexta |
| Celgene Corporation | $24.36 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.24 | 2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $20.57 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Batalha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.